 The emergence of different SARS-CoV-2 variants, including the Armicram variant in November 2021, has resulted in a continuous major health concern at a global scale. Currently, the Armicram variant has spread rapidly worldwide within a short time period and has instilled serious uncertainties on the effectiveness of humoral adaptive immunity generated by COVID-19 vaccination or an active viral infection as well as the protection provided by antibody-based immunotherapies. Amidst such high public health concerns, the need to carry out booster vaccination has been emphasised, and current evidence reveals the importance of incorporating booster vaccination using several vaccine platforms, such as Viral Vector and mRNA-based vaccines, as well as other platforms that are under explorative investigations. Further research is being conducted to assess the effectiveness and durability of protection provided by booster COVID-19 vaccination against Armicram and other SARS-CoV-2 variants.